Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irritation and Sensitization Potential of Selegiline TDS vs EMSAM
NCT07452692Phase 1Completed
- Sponsor
- Corium
- Start
- Aug 2026
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of selegiline transdermal patch in major depressive disorder (MDD), sponsored by Corium. Started Aug 2026; status: completed.
02
Drugs
selegiline transdermal patch
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT07452692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07452692.